A randomised trial examining the effectiveness of sympathetic nervous inhibition in alleviating the metabolic side effects of antipsychotic medications in patients with schizophrenia [ 2012 - 2015 ]

Research Grant

Researchers: Prof Gavin Lambert (Principal investigator) ,  Dr Nora Straznicky ,  Prof David Barton ,  Prof John Dixon

Brief description Despite improved diagnosis and increased use of antipsychotic medications the mortality risk in patients with schizophrenia remains 2-3 times that of the general population, largely due to cardiovascular disease development. In this project we will test the effectiveness of sympathetic nervous inhibition with moxonidine (as add on therapy) in alleviating the metabolic side effects of antipsychotic medications in patients with schizophrenia.

Funding Amount $AUD 477,426.38

Funding Scheme Project Grants

Notes Standard Project Grant